Aequus Boosts Supply Amid Bimatoprost Shortage

Aequus Pharmaceuticals (TSE:AQS) has released an update.

Aequus Pharmaceuticals has ramped up the supply of its Zimed® PF 0.03% bimatoprost eye drops to address the Canadian shortage and ensure continuous patient access to this essential glaucoma treatment. Zimed® PF, which is preservative-free and offered in a multi-dose format, is currently the only option for 0.03% bimatoprost, leading to an expected increase in demand and sales for Aequus. The company’s commitment to addressing the shortage aligns with its focus on developing and commercializing high-quality, differentiated pharmaceutical products.

For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.